Efficient generation of respiratory syncytial virus (RSV)-neutralizing human MoAbs via human peripheral blood lymphocyte (hu-PBL)-SCID mice and scFv phage display libraries

Clinical and Experimental Immunology

Volumn 122, Issue 1, 2000, Pages 85-93

  Nguyena, H ^a   Hay, J ^a,b   Mazzulli, T ^a   Gallinger, S ^a   Sandhu, J ^a   Teng, Y T A ^c   Hozumi, N ^a,d,e  

^a MOUNT SINAI HOSPITAL   (Canada)

^b Faculty of Medicine   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d TOKYO UNIVERSITY OF SCIENCE   (Japan)

^e MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Adjuvant immunization; BIAcore assay; Biopanning; Hypermutation; Passive immunotherapy

Indexed keywords

MESSENGER RNA; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN; VIRUS PROTEIN;

ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; COMBINED IMMUNODEFICIENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOTHERAPY; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTE; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; BASE SEQUENCE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN GAMMA-CHAINS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOCYTES; MICE; MICE, SCID; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE LIBRARY; RECOMBINANT PROTEINS; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL PROTEINS;

EID: 0033771495     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01345.x     Document Type: Article

References (38)

1. Respiratory synctial vires (RSV) disease and prospects for its control
2. National surveillance for RSV, United State
3. Risk of primary infection and re-infection with RSV
4. Infectivity of RSV by various routes of inoculation
5. Expression of the F glycoprotein of RSV by a recombinant vaccinia vires: Comparison of the individual contribution of the F and G glycoprotein to host immunity
6. The G glycoprotein of human RSV of subgroups A and B: Extensive sequence divergence between anfigenically related proteins
7. Neutralization epitopes of the F glycoprotein of RSV: Effect of mutation upon fusion function
8. Serious respiratory tract disease caused by RSV: Prospects for improved therapy and effective immunization
9. Enhanced pulmonary histopathology is observed in cotton rats by prior intramuscular inoculation of formalin inactivated RSV or purified F glycoprotein and challenged with RSV 3-6 months after immunization
10. Prevention of RSV infection: Indication for the use of Palivizumab and update on the use of RSV-IVIG
11. Human primary immune response in SCID mice engrafted with human peripheral blood lymphocytes
12. High level functional engraftment of SCID mice with human PBLs following pmtreatment with radiation and anti-asialo GM1
13. By-passing immunization: Human antibodies from V-gene libraries displayed on phage
14. Effectiveness of topical administered neutralizing antibodies in experimental immunotherapy of RSV infection in cotton rats
15. Immunization of hu-PBL-SCID mice and the rescue of human monoclonal Fab fragments through combinatorial libraries
16. Single chain antibody variable regions
17. Continuous cultures of fused cells secreting antibody of predefined specificity
18. Isolation of a neutralizing human RSV antibody from a dominant, non-neutralizing immune repertoire by epitope-blocked panning
19. Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial vires infection: Significance for subunit vaccines
20. Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure
21. The human immune system in hu-PBL-SCID mice
22. Time-dependent induction of protective anti-influenza immune responses in human peripheral blood lymphocyte/SCID mice
23. Antigen-specific IgG responses from naive human splenocytes: In vitro priming followed by antigen boost in the SCID mouse
24. Molecular analysis of the heavy chain of antibodies that recognize the capsular polysaccharide of Neisseria meningitidis in hu-PBMC reconstituted SCID mice and in the immunized human donor
25. Antigen-specific B and T cells in human/mouse radiation chimera following immunization in vitro
26. Enhancement of specific immunoglobulin production in SCID-hu-PBL mice after in vitro priming of human B cells with superantigen
27. Human monoclonal antibodies specific to hepatitis B virus generated in a human/mouse radiation chimera: The Trimera system
28. Human monoclonal Fab fragments derived from a combinatorial library bind to RSV-F glycoprotein and neutralize infectivity
29. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice
30. Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge
31. Aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants
32. Immunotherapy of respiratory syncytial virus in cotton rats (Sigmodon Fulviventer) using IgG in a small-particle aerosol
33. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice
34. Randomized double-blind comparison of chimeric monoclonal antibody to turnout necrosis factor I (cA2) versus placebo in rheumatoid arthritis
35. Effectiveness of RSVIG prophylaxis and therapy of respiratory syncytial virus in an immunosuppressed animal model
36. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZI9
37. Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease
38. The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops